Skip to main content
SpringerLink
Log in

Steroid hormone receptors in breast cancer management

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Estrogen and progesterone receptors (ER and PR) have now been studied in clinical breast cancer for more than 20 years. Positive receptor status correlates with favorable prognostic features including a lower rate of cell proliferation and histologic evidence of tumor differentiation. During the first several years after diagnosis, patients with ER-positive tumors tend to have a lower recurrence rate; however, this is balanced by a higher recurrence rate in subsequent years so that the overall prognostic significance of receptor status is modest. ER and PR have their greatest utility in predicting response to hormonal therapy, both in the adjuvant setting and for advanced disease. When the assay is done properly and cut-offs for ER-negativity and positivity are defined by clinical studies of patients treated with endocrine therapy, receptor status is very helpful in identifying groups of patients who are very unlikely to benefit from hormonal therapy. Tumors that express both ER and PR have the greatest benefit from hormonal therapy, but those containing only ER or only PR still have significant responses.

Two types of estrogen receptors, ERα and ERβ, have now been identified. Although there is considerable homology between these receptor forms, they appear to have important structural and functional differences that may be important for tissue and promoter- specific regulation of gene expression. These receptor forms, as well as ER variants and mutants, may also contribute to hormonal sensitivity and resistance. PR also exists in two forms, PRA and PRB. PRA appears to have repressor functions on both PRB and ERα, and the ratio of PRA to PRB in clinical breast tumors needs to be studied for its possible clinical relevance. Expression of receptor- interacting proteins can also modulate ER transcriptional activity, and these too need additional study to determine if they are markers of hormonal sensitivity or resistance. In summary, ER and PR status are important biomarkers that help physicians individualize therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jensen EV, DeSombre ER: Mechanism of action of the female sex hormones. Annu Rev Biochem 41:203–230, 1972

    Google Scholar 

  2. Gorski J, Toft DO, Shyamala G, Smith D, Notides A: Hormone receptors: Studies on the interaction of estrogen with uterus. Recent Prog Horm Res 24:45–80, 1968

    Google Scholar 

  3. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888, 1980

    Google Scholar 

  4. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102–1109, 1984

    Google Scholar 

  5. Glass GK, Rose DW, Rosenfeld MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9:222–232, 1997

    Google Scholar 

  6. Osborne CK, Elledge RM, Fuqua SAW: Estrogen receptors in breast cancer therapy. Sci Med 3:32–41, 1996

    Google Scholar 

  7. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167–1177, 1996

    Google Scholar 

  8. Anzick AL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X-Y, Sauter G, Kallioniemi O-P, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968, 1997

    Google Scholar 

  9. Hörlein AJ, Näär AM, Helnzel T, Tochia J, Gloss B, Kurokawa R, Ryan A, Kamel Y, Söderström M, Glass CK, Rosenfeld MG: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397–404, 1995

    Google Scholar 

  10. Li H, Leo C, Schroen DJ, Chen JD: Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. Mol Endocrinol 11:2025–2037, 1997

    Google Scholar 

  11. Nagy L, Kao H-Y, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373–380, 1997

    Google Scholar 

  12. Jackson WA, Richer RK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693–705, 1997

    Google Scholar 

  13. Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657–666, 1997

    Google Scholar 

  14. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89–95, 1994

    Google Scholar 

  15. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443–456, 1995

    Google Scholar 

  16. Kuiper GG, Enmark E, Pelto-Huikko P, Nilsson S, Gustafsson JA: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930, 1996

    Google Scholar 

  17. Mosselman S, Polman J, Dijkema R: ERß: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53, 1996

    Google Scholar 

  18. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863–870, 1997

    Google Scholar 

  19. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS: The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814–825, 1995

    Google Scholar 

  20. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor ß. Mol Endocrinol 11:353–365, 1997

    Google Scholar 

  21. Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 82:2371–2374, 1997

    Google Scholar 

  22. Cowley SM, Hoare S, Mosselman S, Parker MG: Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 272:19858–19862, 1997

    Google Scholar 

  23. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508–1510, 1997

    Google Scholar 

  24. Osborne CK: Receptors. In: Harris J, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases, 2d Edition. JB Lippincott Co, Philadelphia PA, 1991, pp 301–325

    Google Scholar 

  25. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413–416, 1983

    Google Scholar 

  26. Green GL, Sobel NB, King WJ, Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem 20:51–56, 1984

    Google Scholar 

  27. King WJ, Green GL: Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745–747, 1984.

    Google Scholar 

  28. McGuire WL, Vollmer EP, Carbone PP (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975

    Google Scholar 

  29. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz ABJ: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125:107–113, 1990

    Google Scholar 

  30. Millis RR: Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46:2869–2871, 1980

    Google Scholar 

  31. Fisher ER, Osborne CK, McGuire WL, Redmond C, Knight WA, Fisher B, Bannayan G, Walder A, Jacobson AA, Queen DM, Bennett DE, Ford HC: Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1:37–41, 1981

    Google Scholar 

  32. Maynard PV, Davies CJ, Blamey RW, Elston CW, Johnson J, Griffiths K: Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer 38:745–748, 1978

    Google Scholar 

  33. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45:349–353, 1980

    Google Scholar 

  34. Glaubitz LC, Bowen JH, Cox EB, McCarty KS: Elastosis in human breast cancer. Correlation with sex steroid receptors and comparison with clinical outcome. Arch Pathol Lab Med 108:27–30, 1984

    Google Scholar 

  35. Meyer JS, Rao BR, Stevens SC, White WL: Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40:2290–2298, 1977

    Google Scholar 

  36. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9–20, 1993

    Google Scholar 

  37. Walt AJ, Singhakowinta A, Brooks SC, Cortez A: The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 80:506–512, 1976

    Google Scholar 

  38. Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671, 1977

    Google Scholar 

  39. Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63:1271–1277, 1979

    Google Scholar 

  40. Westerberg H, Gustafson SA, Nordenskjold B, Silfversward C, Wallgren A: Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer 26:429–433, 1980

    Google Scholar 

  41. Bishop HM, Blamey RW, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 2:283–284, 1979

    Google Scholar 

  42. Nicholson RI, Campbell FC, Blamey RW, Elston CW, George D, Griffiths K: Steroid receptors in early breast cancer: Value in prognosis. J Steroid Biochem 15:193–199, 1981

    Google Scholar 

  43. Crowe JP, Hubay CA, Pearson OH, Marshall JS, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, McGuire WL: Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2:171–176, 1982

    Google Scholar 

  44. Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53:2525–2529, 1984

    Google Scholar 

  45. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671–675, 1979

    Google Scholar 

  46. Hilsenbeck SG, Ravdin PM, de Moor C, Osborne CK, Clark GM: Paradoxical decreases in prognostic utility as datasets mature: Time-dependent lack of proportional hazards in prognostic factors in primary breast cancer. Breast Cancer Res Treat 37(suppl):35, 1996

    Google Scholar 

  47. Lippman ME, Allegra JC: Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46:2829–2834, 1980

    Google Scholar 

  48. Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G, Heuson JC: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46:2889–2895, 1980

    Google Scholar 

  49. Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K, Haybittle JL: Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2:1317–1319, 1981

    Google Scholar 

  50. Knight WA, Osborne CK, McGuire WL: Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 9:361–368, 1980

    Google Scholar 

  51. Osborne CK, Clark GM, Ravdin PM: Adjuvant systemic therapy of primary breast cancer. In: Harris JR, Lippman ME, Hellman S (eds) Diseases of the Breast. Lippincott-Raven Publishers, Philadelphia PA, 1996, pp 546–576

    Google Scholar 

  52. NATO Steering Committee: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57:608–611, 1988

    Google Scholar 

  53. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office, Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet 2:171–175, 1987

    Google Scholar 

  54. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA, and other NSABP investigators: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4:459–471, 1986

    Google Scholar 

  55. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, in press

  56. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by presence of in-situ carcinoma. J Clin Oncol 10:599–605, 1992

    Google Scholar 

  57. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260–1266, 1994

    Google Scholar 

  58. Seidman AD, Baselga J, Yao T-J, Gilewski T, Rosen PP: HER-2/neu overexpression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer (Abstract 80). Proc Am Soc Clin Oncol 15:104, 1996

    Google Scholar 

  59. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223–1228, 1978

    Google Scholar 

  60. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330–1334, 1978

    Google Scholar 

  61. Clarke CL, Balleine RL, Auchus RJ, Fuqua SAW: Estrogen and progesterone receptor variants in human breast cancer. Current Opin Endocrinol Diabetes 2:398–403, 1995

    Google Scholar 

  62. Fuqua SAW: Estrogen and progesterone receptors and breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven Publishers, Philadelphia PA, 1996, pp 261–271

    Google Scholar 

  63. Lehrer SP, Schmutzler RK, Rabin JM, Schachter BS: An estrogen receptor genetic polymorphism and a history of spontaneous abortion: correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer. Breast Cancer Res Treat 26:175–180, 1993

    Google Scholar 

  64. Karnick PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54:349–353, 1994

    Google Scholar 

  65. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast cancer. Cancer Res 52:483–486, 1992

    Google Scholar 

  66. Zhang Q, Borg A, Fuqua SAW: An exon 5 deletion variant of the estrogen receptor frequently co-expressed with wild-type estrogen receptor in human breast cancer. Cancer Res 53:5882–5884, 1993

    Google Scholar 

  67. Fuqua SAW, Wiltschke C, Castles C, Wolf D, Allred DC: A role for estrogen receptor variants in endocrine resistance. Endocrine-Related Cancer 2:19–25, 1995

    Google Scholar 

  68. Wiltschke C, Lemieux P, Wolf DM, Castles CG, Zhang QX, O'Connell P, Allred DC, Fuqua SAW: Isolation of a super-active estrogen receptor variant from premalignant breast lesions (Abstract). Breast Cancer Res Treat 37(Suppl):40, 1996

    Google Scholar 

  69. Horwitz KB, McGuire WL, Pearson OH, Segaloff A: Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 189:726–727, 1975

    Google Scholar 

  70. Gross GE, Clark GM, Chamness GC, McGuire WL: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44:836–840, 1984

    Google Scholar 

  71. Ravdin PM, Green S, Melink-Dorr T, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest oncology Group Study. J Clin Oncol 10:1284–1291, 1992

    Google Scholar 

  72. Gronemeyer H: Transcription activation by estrogen and progesterone receptors. Ann Rev Genet 25:89–123, 1991

    Google Scholar 

  73. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP: The A and B forms of human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14:8356–8364, 1994

    Google Scholar 

  74. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB: Antagonist-occupied human progester-one B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A receptors. Mol Endocrinol 7:1256–1265, 1993

    Google Scholar 

  75. McDonnell DP, Goldman ME: RU486 exerts antiestrogenic activities through a novel progesterone receptor A-form mediated mechanism. J Biol Chem 269:11945–11949, 1994

    Google Scholar 

  76. Chalbos D, Galtier F: Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J Biol Chem 269:23007–23012, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78284, USA

    C. Kent Osborne

Authors
  1. C. Kent Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osborne, C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51, 227–238 (1998). https://doi.org/10.1023/A:1006132427948

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006132427948

Search

Navigation